Medtronic is deriving a good part of its growth from insulin pumps and blood glucose monitors,says CEO Bill Hawkins.It gets 10% of its topline growth from diabetes products.Ever more sophisticated devices are being developed to combat the chronic disease.Medtronic has been increasing its spending on research and development by over 70% for the past three years.In consequence,they're on the path of closing the loop with diabetes,Mr.Hawkins believes.
Bill Hawkins described a number of the company's diabetes products,such as a sensor you put on your skin for several days that continuously monitors your condition.They're making continuous insulin pumps,and also a sensor that turns the pump off if blood sugar gets too low.Medtronic is working on a pump patch for the abdomen that communicates to a handheld device.They are working toward an artificial pancreas,Mr.Hawkins revealed.Groups of pancreatic cells,the islets of Langerhans,named for 19th century German histologist Paul Langerhans,produce the hormone insulin,which regulates the body's use of carbohydrates.Diabetes is a disruption of this insulin production in the pancreas.
No comments:
Post a Comment